Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren’s disease
Introduction The therapeutic interest of targeting B-cell activating factor (BAFF) in Sjögren’s disease (SjD) can be suspected from the results of two phase II clinical trials but has not been evaluated in an animal model of the disease. We aimed to evaluate the therapeutic efficacy of this strategy...
Saved in:
| Main Authors: | Renaud Felten, Jacques-Eric Gottenberg, Lucienne Chatenoud, Jean Sibilia, Pascal Schneider, Hélène Dumortier, Fanny Monneaux, Anne-Perrine Foray, Cindy Marquet, Coralie Pecquet, Fabrice Valette |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-09-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/10/3/e004112.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients
by: Lucie Aubergeon, et al.
Published: (2024-12-01) -
Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren’s Syndrome
by: Sang Jin Lee, et al.
Published: (2016-01-01) -
Increased BAFF Levels in Children with Acute Brucellosis
by: Emine Hafize Erdeniz, et al.
Published: (2020-03-01) -
Association of BAFF gene polymorphisms with multiple sclerosis progression
by: I. V. Smagina, et al.
Published: (2020-02-01) -
Characterization of BAFF and APRIL subfamily receptors in rainbow trout (Oncorhynchus mykiss). Potential role of the BAFF / APRIL axis in the pathogenesis of proliferative kidney disease.
by: Aitor G Granja, et al.
Published: (2017-01-01)